Make an Inquiry
Accelerating Scleroderma Drug Development

Scleroderma presents significant therapeutic challenges due to its complex pathophysiology and limited treatment options. Protheragen is a specialized partner in Scleroderma drug development, dedicated to advancing novel therapeutics through rigorous preclinical research. Leveraging deep scientific expertise, Protheragen delivers a comprehensive suite of preclinical services spanning target validation, lead optimization, pharmacology, and IND-enabling studies. Our advanced platforms integrate cutting-edge molecular, cellular, and in vivo models tailored to the unique mechanisms of Scleroderma, ensuring translational relevance and robust data generation. Protheragen’s team combines extensive experience in fibrosis biology with a strong track record in regulatory compliance, facilitating seamless progression through critical preclinical milestones. By uniting scientific innovation with operational excellence, Protheragen is committed to accelerating the development of effective therapies and transforming the landscape of Scleroderma treatment.

What is SclerodermaTargets for SclerodermaDrug Discovery and Development ServicesWhy Choose Us

What is Scleroderma

Scleroderma, or systemic sclerosis, is a rare chronic autoimmune connective tissue disease marked by excessive fibrosis, vascular abnormalities, and immune dysregulation. Its pathogenesis involves a complex interplay of genetic susceptibility and environmental triggers, leading to immune-mediated injury, microvascular damage, and activation of fibroblasts. This results in overproduction of collagen and other extracellular matrix components, causing progressive thickening and hardening of the skin and, in many cases, internal organs such as the lungs, heart, gastrointestinal tract, and kidneys. The disease is classified into subtypes including limited and diffuse cutaneous systemic sclerosis, sine scleroderma, and localized forms such as morphea and linear scleroderma. Clinically, scleroderma presents with skin changes, Raynaud phenomenon, digital ulcers, joint contractures, and potential involvement of internal organs, leading to complications like interstitial lung disease, pulmonary arterial hypertension, gastrointestinal dysmotility, and renal crisis. Diagnosis relies on a combination of clinical evaluation, serological testing for specific autoantibodies, imaging studies, and sometimes tissue biopsy. Early recognition is essential for risk stratification and management. Treatment is tailored to organ involvement and may include immunosuppressive agents such as mycophenolate mofetil and rituximab, antifibrotic therapies like nintedanib, and targeted treatments for complications, including bosentan for pulmonary hypertension and aminobenzoate potassium for skin fibrosis.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-656247-17-5-intedanibnintedanib-usan intedanib; nintedanib (USAN) 656247-17-5 C31 H33 N5 O4 539.625
img-147536-97-8-bosentan-rec-inn-usan-jan bosentan (Rec INN; USAN; JAN) 147536-97-8 C27 H29 N5 O6 S 551.614
rituximab (Prop INN; USAN) 174722-31-7
img-128794-94-5-mycophenolate-mofetil-usan-ban mycophenolate mofetil (USAN; BAN) 128794-94-5 C23 H31 N O7 433.495
img-138-84-1-aminobenzoate-potassiumpara-aminobenzoic-acid-pota aminobenzoate potassium; para-aminobenzoic acid potassium salt (USAN) 138-84-1 C7 H6 N O2 . K 175.226

Learn More

Targets for Scleroderma

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
endothelin receptor type B EDNRB
endothelin receptor type A EDNRA
C-C motif chemokine receptor 2 CCR2
cereblon CRBN
DCX (DDB1-CUL4-X-box) E3 protein ligase complex
glutamyl-prolyl-tRNA synthetase 1 EPRS1
tumor necrosis factor TNF
CD19 molecule CD19
Collagen (nonspecified subtype)
lysyl oxidase LOX

Scleroderma is driven by a complex interplay of immune dysregulation, vascular dysfunction, and progressive fibrosis, each governed by distinct molecular targets. Key immune-related targets include Bruton Tyrosine Kinase (BTK), CD19, C-C Motif Chemokine Receptor 2 (CCR2), and Tumor Necrosis Factor (TNF), which orchestrate B cell activation, autoantibody production, and chronic inflammation. Vascular abnormalities are mediated by endothelin receptor subtypes EDNRA and EDNRB, which regulate vasoconstriction, endothelial cell function, and vascular remodeling. Fibrotic processes are fueled by proteins such as Cellular Communication Network Factor 2 (CCN2/CTGF), Lysyl Oxidase (LOX), and Lysyl Oxidase Like 2 (LOXL2), which drive fibroblast activation, myofibroblast differentiation, and excessive extracellular matrix deposition, resulting in tissue stiffness and organ dysfunction. Therapeutically, these targets represent promising intervention points to disrupt disease progression. BTK and CD19 inhibitors are being evaluated for their ability to suppress B cell-driven autoimmunity, while CCR2 antagonists aim to reduce monocyte infiltration and inflammation. Endothelin receptor antagonists, such as bosentan and ambrisentan, are already approved for managing Scleroderma-associated pulmonary arterial hypertension and digital ulcers. Antifibrotic agents targeting CCN2, LOX, and LOXL2 are in various stages of preclinical and clinical development, offering hope for directly addressing tissue fibrosis. Collectively, these molecular targets underpin a precision medicine approach, with ongoing research aiming to translate mechanistic insights into effective, targeted therapies for Scleroderma.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Scleroderma drug discovery by providing robust, disease-relevant screening and characterization platforms. We utilize advanced biochemical and cell-based assays, including flow cytometry, ELISA, FRET, HTRF, chemiluminescence, and mass spectrometry, to evaluate compound potency, mechanism, and target engagement across key fibrotic and immune pathways. Comprehensive pharmacological parameter analysis—EC-50, IC-50, Kd, and more—supports precise lead optimization. Our expertise in profiling targets such as BTK, Cereblon, ENPP2, ETA, ITK, and TNF ensures actionable insights, enabling informed candidate selection and effective preclinical development for Scleroderma therapies.

Bruton Tyrosine Kinase Cereblon
Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 Endothelin Receptor Type A
Glutamyl-Prolyl-Trna Synthetase 1 Il2 Inducible T Cell Kinase
Tumor Necrosis Factor

Learn More

Why Choose Us

Choosing Protheragen means partnering with a team dedicated to advancing the field of Scleroderma therapeutics through specialized expertise and unwavering professionalism. At Protheragen, we have developed a deep understanding of Scleroderma pathology and drug development, allowing us to design and execute preclinical studies that are both innovative and effective. Our professional teams consist of experienced scientists and industry experts who utilize advanced technology platforms to accelerate the discovery and development of novel therapeutics. With a proven track record in delivering reliable preclinical drug development services, Protheragen has become a trusted partner for clients seeking high-quality results. We adhere to the strictest quality standards and regulatory compliance, ensuring that every project meets or exceeds industry expectations. Above all, Protheragen is committed to making meaningful contributions to Scleroderma research, striving to bring new hope to patients by advancing promising therapies from concept to clinic. Partner with Protheragen for dependable, expert-driven support in your Scleroderma drug development journey.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Scleroderma?

A: Scleroderma presents unique preclinical challenges due to its complex pathophysiology, including heterogeneity in disease presentation, involvement of multiple organ systems, and limited availability of robust animal models that accurately recapitulate human disease. At our company, we address these challenges by leveraging advanced in vitro and in vivo models, including humanized systems and multi-organ fibrosis models, to ensure translational relevance and predictive value for clinical outcomes.

Q: What regulatory considerations should be taken into account during Scleroderma drug development?

A: Regulatory agencies such as the FDA and EMA require comprehensive data on safety, efficacy, and mechanism of action, especially for rare and complex diseases like Scleroderma. Our team ensures that all preclinical studies are designed in compliance with GLP standards, and we provide thorough documentation for IND-enabling studies. We also advise on orphan drug designation strategies and support interactions with regulatory bodies to facilitate a smooth transition to clinical phases.

Q: What are the key technical aspects to consider in preclinical Scleroderma research?

A: Technical considerations include the selection of disease-relevant endpoints, biomarkers for fibrosis and immune modulation, and the use of validated animal models such as bleomycin-induced fibrosis or genetically engineered mice. Our expertise covers the development of custom assays for collagen deposition, skin thickness, and organ-specific fibrosis, as well as advanced imaging and molecular profiling techniques to provide comprehensive efficacy and safety assessments.

Q: What is the typical timeline and cost for preclinical development of a Scleroderma drug candidate?

A: The preclinical phase for Scleroderma drug development typically spans 18-36 months, depending on the complexity of efficacy and safety studies required. Costs can vary widely but generally range from $2 million to $6 million for a full IND-enabling package. We work closely with clients to develop customized project plans and budgets, ensuring efficient resource allocation and timely completion of milestones.

Q: What are the critical success factors in preclinical drug development for Scleroderma?

A: Success in Scleroderma drug development hinges on selecting relevant preclinical models, identifying robust translational biomarkers, and designing studies that anticipate clinical endpoints. Early engagement with regulatory authorities and strategic planning for orphan indications are also key. Our company’s integrated approach—combining scientific expertise, regulatory insight, and state-of-the-art technology—maximizes the likelihood of advancing promising candidates to clinical trials.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.